Know Cancer

or
forgot password

Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study


N/A
40 Years
90 Years
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study


Inclusion Criteria:



- Invasive breast cancer post-menopausal women

- Estrogen and/or progesterone receptor positive

Exclusion Criteria:

- Patients with endocrine disease

- Hormone therapy users or those who had been pregnant in the last 12 months before the
diagnosis

- Patients with a negative expression for estrogen and/or progesterone receptors

- Women with a history of thromboembolism

- Patients who had previously undergone any treatment for breast cancer

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Basic Science

Outcome Measure:

Expression of progesterone

Outcome Time Frame:

end of the study (june 2008)

Safety Issue:

No

Principal Investigator

Andre Mattar, MD

Investigator Role:

Principal Investigator

Authority:

Brazil: Ethics Committee

Study ID:

0904/04

NCT ID:

NCT01016665

Start Date:

April 2005

Completion Date:

June 2008

Related Keywords:

  • Breast Cancer
  • Breast cancer
  • Short Term
  • Homontherapy
  • aromatase inhibitor
  • Short term hormonetherapy in breast cancer
  • Breast Neoplasms

Name

Location